The global glioblastoma multiforme market is experiencing strong growth with launch of a novel drug for brain tumors by key players

 

The growing incidence of brain tumors is projected to foster the growth of the global glioblastoma multiforme market during the forecast period. As per the National Foundation for Cancer Research, GBM is the deadliest type of brain cancer, accounting for 45% of all malignant brain tumors. Furthermore, according to the article published by the National Brain Tumor Society, over 10% of people with brain tumors are at high risk of developing glioblastomas. Additionally, key players in the market are involved in joint ventures and partnerships to develop and commercialize novel drugs, in order to strengthen their business in the global glioblastoma multiforme market. For instance, in May 2017, DelMar Pharmaceuticals formalized the collaboration agreement with PRA Health Sciences to conduct phase 3 trials of VAL-083 for the treatment of recurrent GBM.

North America is expected to dominate the global glioblastoma multiforme market and this is attributed to the increasing drug approvals and launches for GBM treatment is again expected to boost the growth of the global glioblastoma multiforme treatment market. For instance, in January 2020, Pfizer launched ‘Zirabev’ in the U.S., which is a bevacizumab biosimilar of Avastin, approved for the treatment of recurrent glioblastoma multiforme. The biosimilar was approved by FDA in June 2019 for the treatment of metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma multiforme, recurrent/persistent or metastatic cervical cancer, and metastatic renal cell carcinoma.

1.      In October 2019, Denovo Biopharma, a San Diego-based biotech company, was granted the U.S. Food & Drug Administration (FDA) approval for its phase 2b clinical trial evaluating an analytical combination therapy for the treatment of newly diagnosed glioblastoma multiforme patients

2.      In March 2018, the Australia-based Kazia Therapeutics, a biopharma company, started phase II clinical trials in the U.S. for its drug, GDC-0084. It is a novel vaccine, Rindopepimut, is in last-stage development in Australia and India for first-line GBM treatment

3.      In December 2020, CNS Pharmaceuticals, Inc. announced that FDA has approved an investigational new drug application for berubicin for the treatment of patients with glioblastoma multiforme

Glioblastoma Multiforme is the second most serious of all the gloom, a group of generally benign tumors growing in the cranial cavity or their central nervous system, usually in the jaw area. Generally diagnosed when symptoms are noticed, GBM usually grows slowly and over time. Clinically, glioblastomas are classified into four different grades; however, the third most serious, grade 4 or GBM, is the commonest in human beings. Like all other types of cancer, the first stage of GBM is usually the least dangerous, though it may produce symptoms that are indicative of other, more serious conditions. The third and fourth stages of GBM are considered more dangerous due to the more frequent emergence of secondary sites and the increased ability for secondary GBM to migrate.